Opdivo is a prescription immunotherapy medication containing nivolumab 40 mg, a fully human monoclonal antibody used to treat various types of cancer.
Nivolumab belongs to a class of drugs called immune checkpoint inhibitors.
Opdivo is indicated for the treatment of several cancers including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (kidney cancer), classical Hodgkin lymphoma, head and neck squamous cell carcinoma, and urothelial carcinoma (bladder cancer), among others.